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Abstract
Background: Epidemiological data on the causes of pleural effusion (PE) are scarce. Data on the lo-
cal prevalence of various causes of PE may play a crucial role in the management strategy of patients 
with PE. The aim of the study was to investigate the causes of PE and to assess 30-day mortality rate 
in unselected adult patients treated in a large, multidisciplinary hospital. 
Methods: Retrospective analysis of medical records, including chest radiographs, of 2835 consecutive 
patients admitted to the hospital was performed. Radiograhic signs of PE were found in 195 of 1936 
patients in whom chest radigraphs were available. These patients formed the study group. 
Results: The leading causes of PE were as follows: congestive heart failure (CHF; 37.4%), pneumo-
nia (19.5%), malignancy (15.4%), liver cirrhosis (4.2%) and pulmonary embolism. The cause of PE 
in 6.7% patients was not established. There was a significant predominance of small volume PE as 
compared to a moderate or large volume PEs (153, 28 and 14 patients, respectively). Almost 80% of 
patients with CHF presented with small volume PE, while almost 50% of patients with malignant PE 
demonstrated moderate or large volume PE. Thirty-day mortality rate ranged from 0% for tuberculous 
pleurisy to 40% for malignant PE (MPE). 
Conclusions: Pleural effusion was found in 10.1% of patients treated in a large multidisciplinary 
hospital. CHF was the leading cause of PE. Although 30-day mortality in patients with CHF was rela-
tively high, it was lower than that in parapneumonic PE and MPE. (Cardiol J XXXX; XX, X: xx–xx)
Key words: epidemiology, pleural effusion, congestive heart failure, pleuritic,  
pneumonia, tuberculosis, cancer
Introduction
Pleural effusion (PE) affects approximately 
1.5 million patients per year in the United States 
[1]. This condition may be associated with a wide 
range of underlying diseases, including pneumonia, 
tuberculous pleurisy, malignancies, chronic heart 
failure, liver cirrhosis and many other diseases. 
Therefore, causative diagnosis in patients with 
PE is challenging and often requires not only a 
thorough clinical assessment but also the use of 
different imaging techniques, diagnostic thoracen-
tesis with pleural fluid analysis, pleural biopsy and/
or thoracoscopy. As some of the above procedures 
are relatively invasive, it is critically important to 
properly select patients who require comprehen-
sive diagnostics. In this context, epidemiological 
data on the local prevalence of different causes of 
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PE may play a crucial role in the management strat-
egy of patients with this condition. For instance, 
a predominance of benign and self-limited under-
lying diseases questions the necessity of more 
advanced diagnostic procedures in a significant 
proportion of patients with PE.
According to data from the United States, 
the most common cause of PE was congestive 
heart failure (CHF) — 36.3%, while the relative 
incidence of malignant (MPE) and tuberculous 
pleural effusion (TPE) among all patients with PE 
was 14.5% and 0.2%, respectively [1]. In contrast, 
a retrospective analysis of all patients with PE 
who underwent diagnostic thoracentesis over a 
19-year period at a university hospital in Spain 
showed that malignancies and tuberculosis (TB) 
were responsible for approximately 2-fold, and 
45-fold higher percentage than those reported in 
the United States (27.3% and 9%, respectively). 
In one fifth of 3077 patients with PE (20.8%), 
CHF was diagnosed as an underlying disease [2]. 
It was most prevalent in elderly patients (45% of 
all causes were in patients older than 80 years of 
age), while TB was the most common etiology in 
patients < 34 years of age (52% of all causes of PE 
in this age group) [2].
Comparison of the above studies demonstrates 
that the epidemiological data should be interpreted 
with caution, as they may show significant lo-
cal variability. This is because they are affected 
by a number of factors, such as ethnicity, local 
burden of different diseases, age structure of the 
population and the availability and quality of a 
healthcare system. Tuberculous PE may serve as 
a good example. There are not only huge regional 
differences in the incidence rate of TB, but also 
significant differences in TB manifestations. In 
regions with low and intermediate TB incidence, 
only 2–5% of all TB patients present with TPE 
[3, 4]. On the other hand, in low income and high 
TB incidence countries the percentage of patients 
with TPE in TB patients can be as high as 22.8% 
and 68.8% [5, 6].
The undeniable progress in healthcare quality 
over the years has undoubtedly affected epide-
miological data. The age adjusted death rate for 
the leading cause of mortality, i.e. cardiovascular 
diseases (CVDs), has decreased since 1993. The 
annual death rate for the second leading cause of 
mortality, i.e. lung cancer decreased from 91.1 in 
1990 to 49.8 in 2015 [7]. Deaths from these two 
conditions accounted for as many as 45.3% of all 
deaths in the United States in 2015 [8].
Cardiovascular diseases have also been a 
leading cause of death in Poland. For a number of 
years, nearly half of all deaths have been caused 
by CVDs. Nonetheless, in the last few decades, a 
gradual decline in relative death rate from CVDs 
has been observed. At the same time a change 
in the relative contribution of deaths associated 
with coronary artery disease and CHF was noted, 
with a significant decline for the first and an in-
crease for the latter [9]. Significant changes in 
the epidemiology of two other common causes of 
PE, i.e. TB and malignancies were also reported. 
In Poland, the relative incidence of TB pleurisy 
decreased from 2.7% to 1.9% between 2002 and 
2006 and to 0.9% in 2015 [10]. Mortality due 
to breast cancer increased from 28.2 to 86.3 per 
100,000 between 1980 and 2013. At the same time, 
lung cancer mortality increased from 29.6 to 56.0 
over the same period [11].
According to available research, there are 
no current data on the etiology of PE effusion in 
Central and Eastern Europe. Therefore, a pilot 
study herein was undertaken on the causes of PE 
in all patients admitted to a large multidisciplinary 
teaching hospital.
The specific study objectives were as follows: 
(i) to determine the causes of PE in a non-selected 
group of patients admitted to a multidisciplinary 
teaching hospital located in a large urban area; (ii) 
to assess 30-day mortality in hospitalized patients 
with PE.
Methods
This retrospective cross-sectional study was 
performed at the Central Teaching Hospital of the 
Medical University of Warsaw, Poland. This is a 
multidisciplinary hospital with more than 1000 
beds which provide medical services on different 
levels. 
The study included all patients admitted to the 
hospital between January 1st and February 1st, 2017. 
Data were extracted from the Hospital Information 
System and Picture Archiving and Communication 
System (PACS). Chest radiographs of all patients 
were initially analyzed by two medical faculty stu-
dents to identify all radiographs with radiological 
signs of PE. The findings were further confirmed 
by two pulmonologists, who also reviewed other 
imaging studies (e.g. computed tomography scans 
and thoracic ultrasound) of these patients. Only 
patients with pleural effusion confirmed by both 
pulmonologists were included in further analysis. 
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Cause of PE was determined by the analysis of 
medical data and reports, radiology and labora-
tory findings. Definitions and criteria used for the 
diagnosis of underlying diseases were consistent 
with those presented in the previous studies [12, 
13]. Patients in whom the available data were insuf-
ficient to make a diagnosis, were allocated to the 
“undiagnosed pleural effusion” group. At the next 
stage, 30-day mortality was assessed with the date 
of the first chest radiograph with PE construed as 
day “zero”.
Laterality and semiquantitative assessment 
of pleural fluid volume were based on chest radio-
graphs performed in the erect position (standing or 
sitting). Pleural effusions were classified as small 
when occupied ≤ 1/3 of the ipsilateral hemithorax 
on plain chest radiograph, moderate when occupied 
between 1/3 and 2/3 of the hemithorax, and large 
when occupied more than 2/3 of the hemithorax.
Statistical analysis
Data are presented as median and interquartile 
ranges (IQR). The D’Agostino-Pearson test was 
used to assess normality of data distribution. Dif-
ferences between continuous variables were tested 
using the Kruskal-Wallis or Mann-Whitney U test. 
Categorical variables were expressed as numbers 
and percentages and were compared using the 
Fisher exact test. All p values were 2-tailed and 
p < 0.05 was considered statistically significant. 
Statistical analysis was performed with MedCalc 
statistical software version 18.5 (MedCalc Software 
bvba, Ostend, Belgium).
Results
Four thousand one hundred and sixty-eight 
patients were admitted to the hospital between 
January 1st and February 1st, 2017. Almost 70% of 
these patients (2835) were admitted to non-surgical 
departments, while the remaining patients (1333) 
were admitted to surgical departments or inten-
sive care unit. Chest radiographs were performed 
in 1936 patients and in 220 of these, radiographic 
signs of PE were initially identified. The initial 
findings were further verified by pulmonary spe-
cialists and 195 patients with chest radiographs 
demonstrating PE were eventually selected.
The most common cause of pleural effusion 
was heart failure, which accounted for 37.4% of 
cases. The second most common cause was par-
apneumonic effusion (19.5%) and the third was 
malignant pleural involvement (15.4%). Detailed 
data on PE etiology are presented in Figure 1.
The median age of patients with PE caused 
by CHF was 80 (IQR 70–87) years and was sig-
nificantly higher than that of patients with par-
apneumonic pleural effusion (PPE) and MPE, 
p = 0.01. Thirty-day mortality in CHF was 19.2%, 
and this percentage was 9.7% lower than in PPE 
Congestive heart failure
37.4%
Parapmeumonic effusion
19.5%
Malignant pleural effusion
15.4%
Iatrogenic 5.6%
Liver cirrhosis with ascites 4.2%
Pulmonary embolism 2.6% Gastrointestinal disease 2%
Pleural injury 2.6% Tuberculosis 1.5%
Chronic kidney disease 1.5%
Nephrotic syndrome 1%
Unknown 6.7%
Figure 1. Percentage of patients with various causes of pleural effusion in the investigated group.
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(p = 0.24) and 21.8% lower than in MPE (p = 0.027). 
Comparative analysis of patients with the most 
common causes of pleural exudate did not reveal 
significant differences in terms of gender distri-
bution and 30-day mortality. Patients with TPE 
were significantly younger than patients with PPE, 
p = 0.024. There was also a relevant (although 
statistically insignificant) difference between the 
age of TPE and PPE patients (Table 1). 
The vast majority of patients (n = 153) pre-
sented with small volume of pleural fluid. The 
most common causes of PE in patients with small 
amount of fluid were CHF 40.7%, PPE (17.6%), 
and MPE (11.1%), p < 0.0001 (Fig. 2). Similarly, 
in patients with moderate volume pleural effusion 
CHF (41.4%) was also the most common underly-
ing disease, followed by MPE (20.7%), and PPE 
(6.9%), p = 0.02. There were only 14 patients with 
large volume pleural effusion and the differences 
between the number of patients with other under-
lying diseases did not reach statistical significance. 
There was a significantly uneven distribution 
of PE volume in patients with CHF and PPE, with 
a marked predominance (77.2%) of small volume of 
pleural fluid. Even though over half of the patients 
with MPE were found to have a small amount of 
PE, 47.8% of these patients had a moderate to large 
volume of pleural fluid (Fig. 3).
The prevalence of CHF, MPE and PPE in 
relation to pleural fluid volume and its localization 
(unilateral or bilateral) is shown in Table 2.
Discussion
The present analysis of chest radiographs and 
medical records of almost 2000 patients treated 
in one of the largest multidisciplinary hospitals 
in Poland showed that PE was present in 10.1% 
of patients. The most common cause of PE was 
heart failure (37.4%), followed by parapneumonic 
(19.5%) and malignant (15.4%) effusion. Impor-
tantly, CHF alone was responsible for a number of 
cases comparable to the summed number of cases 
caused by the three other of the most common 
entities associated with PE, i.e. parapneumonic 
pleural effusion, pleural malignancies and hepatic 
hydrothorax (73 vs. 76 patients, respectively). 
Thus, these results emphasize the role of CHF as 
Table 1. Comparative analysis of patients with various causes of pleural exudate.
PPE (n = 38) TPE (n = 3) MPE (n = 30) Others (n = 9) P
Sex:  
male/female
17 (44.7%)/ 
/21 (55.3%)
3 (100%)/ 
/0 (0%)
14 (46.7%)/ 
/16 (53.3%)
3 (33.3%)/ 
/6 (66.7%)
0.2
Age [years]* 76.5 (67–89.3) 44 (29.7–50) 70.3 (62.25–79.5) 69.9 (56–81) 0.014**
30-day mortality 11 (28.9%) 0 (0%) 12 (40.0%) 1 (11.1%) 0.27
Affected side:  
L/R/B
10 (26.3%)/17 
(44.7%)/11 (28.9%)
1 (33.3%)/2 
(66.6%)/0 (0%)
8 (26.7%)/15 
(50%)/7(23.3%)
1 (11.1%)/7 
(77.8%)/1 (11.1%)
0.6377
*Results presented as median (interquartile range); **Significant difference between PPE vs. TPE (p = 0.024); B — bilateral; L — left;  
MPE — malignant pleural effusion; PPE — parapneumonic pleural effusion; R — right; TPE — tuberculous pleural effusion
A B C
30.6%
40.7%
17.6%
CHF PPE MPE Other
11.1%
20.7%
6.9%
41.4%
31.0%
9.0% 9.1%
36.4%
45.5%
Figure 2. Distribution of underlying causes of pleural fluid formation in patients with small (n = 158; A), moderate 
(n = 28; B) and large (n = 14; C) volume of pleural effusion; CHF — congestive heart failure; MPE — malignant pleural 
effusion; PPE — parapneumonic pleural effusion.
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the most common underlying disease in patients 
with PE and indicate that CHF should be a major 
differential diagnosis in these patients. It was also 
observed that almost 80% of patients with CHF 
presented with only a small volume PE. 
According to available research, this is the 
most recent and one of the very few studies from 
Central or Eastern Europe presenting epidemio-
logical data on the causes of PE. In fact, the pre-
vious study which evaluated the incidence of PE 
in a well-defined region of Central Bohemia was 
published 25 years ago. Although there were nu-
merous differences between the current study and 
a study by Marel et al. [14], both studies showed 
that CHF was, and still is, the most common cause 
of PE in Central Europe.
Several important studies on the causes of 
PE have been performed in other countries and 
world regions. In 2014, Porcel et al. [2] published 
the results of a Spanish study which included data 
on 3007 patients who underwent diagnostic thora-
centesis during the previous 19 years. The authors 
found that the most common cause of pleural fluid 
were pleural malignancies (27.3%), while heart 
failure was the second leading cause responsible 
for 20.8% of cases [2]. Chronic heart failure is be-
lieved to be the most common cause of PE in the 
United States. The estimated annual incidence of 
various causes of PE in this country showed that 
CHF was responsible for 36.3% of cases [1]. Pleural 
effusion associated with CHF was 1.7 and 2.5-fold 
more common than PPE and MPE, respectively 
[1]. The differences between the results of vari-
ous studies are multifactorial and were related not 
only to local epidemiological situations and study 
group characteristics, but also to the definitions 
and methods used in the particular studies. For 
instance, only patients who underwent diagnostic 
thoracentesis were included in the study by Porcel 
et al. [2]. This obviously may result in selection 
Figure 3. Differences between distribution of pleural fluid volume in patients with various causes of pleural effusion; 
CHF — congestive heart failure; MPE — malignant pleural effusion; PPE — parapneumonic pleural effusion.
0%
10%
20%
30%
40%
50%
Small
Moderate
Large
60%
70%
80%
90%
100%
CHF PPE MPE Other
Table 2. The percentage of patients with unilateral and bilateral pleural effusion and various effusion 
causes (congestive heart failure, parapneumonic effusion and malignant pleural effusion) in relation to 
pleural fluid volume (small, moderate and large). Percentages form 100% in each pleural fluid volume 
category (small, moderate and large).
Pleural fluid volume
Small Moderate Large
UL B p UL B p UL B p
CHF 28% 31% 30% 30% 10% 0%
PPE 17%` 8% 0.05 5% 5% 0.79 30% 10% 0.85
MPE 13% 3% 20% 10% 40% 10%
B — bilateral; CHF — congestive heart failure; MPE — malignant pleural effusion; PPE — parapneumonic pleural effusion; UL — unilateral
} } }
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bias, as according to common guidelines, not all 
patients with PE due to heart failure require di-
agnostic thoracentesis [15]. On the other hand, 
a high level of agreement between different stud-
ies in terms of the three most common causes of 
PE should be noted. The numerical data found in 
the present study is fully consistent with United 
States data published by Light [1]. To show this 
agreement, data from three different publications 
are presented in Table 3.
A significant proportion of patients with PE 
due to CHF may have various practical implica-
tions. Although a diagnostic thoracentesis to 
differentiate between transudate and exudate 
is necessary only in a small proportion of these 
patients, the high overall number of patients with 
PE due to CHF may result in a significant number 
of patients undergoing the procedure. In this con-
text, it should be remembered that Light’s criteria 
were commonly applied to differentiate between 
transudate and exudate and were only moderately 
specific for exudate. Hence, even more than 20% of 
transudates (mainly due to CHF) can be incorrectly 
classified as exudates [16]. Therefore, additional 
criteria distinguishing between pleural transudate 
and exudate have been proposed for patients with 
suspicion of CHF-related PE which was classified 
as exudate by Light’s criteria. These include pleu-
ral fluid-serum albumin gradient and pleural fluid 
or serum N-terminal pro-B-type natriuretic peptide 
levels [17–19]. It should also be noted that, in spite 
of a high diagnostic sensitivity of Light’s criteria for 
PE, some MPEs can be diagnosed as transudates. 
In a study by Ferreiro et al. [20] 26/281 (9.3%) of 
pleural transudates were caused by malignancies. 
Due to the anatomical and functional relation-
ships, PE in patients with CHF is mainly related to 
left ventricular failure. Also, the number of patients 
with left ventricular dysfunction or dysfunction 
of both ventricles is significantly higher than the 
number of patients with right ventricular failure 
[21]. Therefore, in daily clinical practice, the vast 
majority of PEs in patients with CHF is related to 
left ventricular dysfunction. Nonetheless, PE may 
also be associated with right ventricular failure. 
Tang et al. [22] found PE in 19 of 147 patients (13%) 
with isolated right heart failure due to idiopathic 
or familial pulmonary hypertension.
The prevalence of PE depends on the sensi-
tivity of methods used to detect pleural fluid. As 
the majority of patients with CHF-related PE have 
small volume effusions, the sensitivity of imaging 
methods may significantly affect the results of 
studies on PE in CHF. It has been shown that plain 
chest radiograph (CXR) revealed PE only in 25% of 
patients in a series of 447 patients with heart failure 
[23]. On the other hand, the use of more sensitive 
tools, such as computed tomography, ultrasound 
or autopsy resulted in a much higher reported PE 
prevalence (even more than 80%) [24–26]. 
As mentioned above, the volume of CHF-related 
PE is usually small. This was also the case in the 
present study. More than 77% of patients with PE 
due to CHF presented with only small volume of 
pleural fluid. These results are consistent with data 
published by Porcel and Vives [27].
Table 3. Comparison of data on causes of pleural effusion presented by various authors.
Disease Light et al. [1] 
(2011)
N = 1,377,500
Porcel et al. [2] 
(2014)
N = 3077
Korczynski et al.  
(current study)
N = 195
Congestive heart failure 36.3% 20.8% 37.4%
Parapneumonic effusion 21.8% 18.9% 19.5%
Malignant pleural effusion 14.5% 27.3% 15.4%
Pulmonary embolism 10.9% 1.6% 2.6%
Liver cirrhosis with ascites 3.6% 3.2% 4.2%
Gastrointestinal disease 1.8% 3.6% 2.0%
Tuberculosis 0.2% 8.9% 1.5%
Post-CABG surgery 3.6% 1.0% NA
Pleural injury NA 2.5% 2.6%
Other 7.3% 9.1% 8.1%
Unknown NA 3.1% 6.7%
CABG — coronary artery bypass grafting; NA — not applicable
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In the current study 51% of patients with PE 
due to CHF presented with bilateral pleural fluid. 
This number is lower than that reported in previous 
studies. Woodring et al. [28] found bilateral pleural 
involvement in 72.5% of patients with pleural ef-
fusion due to CHF. Also, the study by Porcel and 
Vives [27] published in 2006 showed virtually the 
same percentage of patients with bilateral pleural 
effusion (70%). On the other hand, later studies 
by Porcel [29] and de Araujo et al. [30] reported 
that the percentages of patients with bilateral PE 
were only slightly higher than demonstrated in the 
present study (61% and 51%, respectively). Again, 
the differences between the results of these stud-
ies can probably be largely attributed to methods 
of pleural fluid detection. 
In the present study, 30-day mortality rate in 
patients with various causes of PE ranged from 
0% to 40%. Thirty-day mortality rate for CHF was 
19.2%. This number seems to be high when com-
pared to data published by Maggioni et al. [31] or 
Tyminska et al. [32]. These authors reported 1-year 
mortality rate in all patients admitted to hospital 
for acute HF 17.4% and 13–21%, respectively. 
However, there were many differences between 
the studies that may have been responsible for the 
fact that the 30-day mortality rate in the current 
study was not comparable to 1-year mortality rate 
in studies by Maggioni et al. [31] and Tyminska et 
al. [32]. These include a primarily lower age with a 
median of 71 (IQR 61–79) years and selection of all 
patients with acute HF. What is worth emphasizing, 
pulmonary congestion was an independent predic-
tor of all-cause 1-year mortality with a hazard ratio 
(95% confidence interval): 2.73 (1.71–4.35) [31]. 
It is suspected that the present results remain in 
agreement with previously cited studies and the 
presence of PE in heart failure patients is a nega-
tive prognostic factor.
Limitations of the study
There are some limitations in the present 
study. First, data for analysis were collected from 
only 1 month during winter. Hence, although the to-
tal number of patients in whom CXR was performed 
was almost 2000, the number of patients with PE 
was relatively low in the context of an epidemio-
logical study [31]. Furthermore, there might have 
been a bias in the true annual proportion of patients 
with different causes of PE related to seasonal 
infections [33]. Second, CXR was the only tool to 
select patients with PE. It may be supposed that 
the use of more sensitive tools could have resulted 
in an even higher percentage of patients with a 
diagnosis of small volume PE. Third, this study 
included only hospitalized patients. This probably 
refers also to patients with CHF, as many of these 
patients did not require diagnostic thoracentesis 
and could have been be treated as outpatients 
[34]. Finally, the present results could have been 
affected by the profile of hospital departments and 
predominating spectrum of their patients.
Conclusions
Pleural effusion was found in 10.1% of patients 
treated in a large multidisciplinary hospital. CHF 
was responsible for 37.4% of all cases. Almost 80% 
of patients with CHF-related PE presented with 
only a small volume of pleural fluid. Although 30-day 
mortality in patients with CHF with PE was rela-
tively high, it was lower than that in PPE and MPE.
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